Skip to Content

Akten FDA Approval History

FDA Approved: Yes (First approved October 7, 2008)
Brand name: Akten
Generic name: lidocaine hydrochloride
Dosage form: Ophthalmic Gel
Company: Akorn, Inc.
Treatment for: Ocular Anesthesia

Akten (lidocaine hydrochloride) Ophthalmic Gel is a topical, ocular anesthetic formulation for use in ocular procedures that require a topical anesthetic agent.

Development Timeline for Akten

Oct  8, 2008Approval Akorn, Inc. Announces the FDA Approval of Akten Ophthalmic Gel 3.5%
Jun  4, 2008Akorn, Inc. Receives NDA Approvable Letter for Akten Ophthalmic Gel 3.5%
Jun 29, 2007Akorn, Inc. Announces the New Drug Application Filing for Akten

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.